CDKN2A and melanoma: CDKN2A mutations have been implicated in approximately 20-40% of familial melanomas.[54] ANRIL is thus believed to participate directly in epigenetic transcriptional repression.[53, 55] Apart from melanoma, ANRIL expression was upregulated in various other malignancies, such as colorectal cancer [56] and NSCLC.[57]